Dose Insider / Outsourcing pharmacies / Quva Pharma, Inc.

Quva Pharma, Inc.FDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

Quva Pharma, Inc. in Sugar Land, Texas is registered with FDA as a 503B outsourcing facility, first on September 10, 2015 and most recently on October 23, 2026. FDA last inspected it on May 4, 2026 and issued a Form 483 with 3 observations.

3 observationsin the Form 483 of FDA’s inspection on May 4, 2026
Observations in the last Form 483FDA inspection reports of registered outsourcing facilitiesQuva Pharma, Inc.3Median facility5Most in one report16Observations in the lastForm 483FDA inspection reports of registered outsourcingfacilitiesQuva Pharma, Inc.3Median facility5Most in one report16

Quva Pharma, Inc. had fewer observations than the median inspected facility.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilityQuva Pharma, Inc.
LocationSugar Land, Texas
Type503B outsourcing facility
Registered sinceSeptember 10, 2015
Latest registrationOctober 23, 2026
Last FDA inspectionMay 4, 2026
Inspection dates4/20/2026 to 5/4/2026
Form 483Issued, 3 observations
FDA action after the inspectionResponse Letter Issued 10/16/2026; FMD-145 Issued 10/19/202
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs0

What did FDA’s investigators observe?

The Form 483 from the inspection of 5/4/2026 lists 3 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2

What the observation is aboutObservations
Sterility and aseptic processing2
Cleaning and disinfection1

FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.

Has this facility recalled any drugs?

FDA’s enforcement reports list 37 recalled products from this facility, from March 30, 2016 to June 24, 2026: 2 in Class I, 33 in Class II, 2 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2026-06-24IIMethohexital SodiumFailed Impurities/Degradation Specifications
2025-10-10IIR.E.C.K. (Ropivacaine HClPresence of Particulate Matter
2025-03-06IIfentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl Lack of Assurance of Sterility
2025-03-06IIfentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 10Lack of Assurance of Sterility
2025-03-06IIfentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 20Lack of Assurance of Sterility
2020-05-28IIoxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium ChlorideSubpotent drug - Product did not contain drug.
2020-04-23IIIR.E.C.K. (RopivacainePresence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac
2019-11-12IIfentaNYL 2000 mcg/100 mL (20 mcg/mL) in 0.9% Sodium ChloridePresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

The table shows 8 of the 37 recalls; the rest are in FDA’s enforcement reports.

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

17 of the 100 facilities on FDA’s list are in Texas. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Form FDA 483, inspection of Quva Pharma, Inc., 4/20/2026 to 5/4/2026. fda.gov
  3. FDA. Drug recall enforcement reports for Quva Pharma, Inc., read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider